Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012

Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Ravit Geva, Hyun Cheol Chung, Chia Chi Lin, Deepti Aurora-Garg, Archana Ray, Kumudu Pathiraja, Jonathan Cheng, Laura Q.M. Chow, Robert Haddad

Research output: Contribution to journalArticle

Abstract

Background: Second-line treatment options for advanced head and neck squamous cell carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety and the efficacy of pembrolizumab for the treatment of HNSCC after long-term follow-up. Methods: Multi-centre, non-randomised trial included two HNSCC cohorts (initial and expansion) in which 192 patients were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks (initial cohort; N = 60) or 200 mg every 3 weeks (expansion cohort; N = 132). Co-primary endpoints were safety and overall response rate (ORR; RECIST v1.1; central imaging vendor review). Results: Median follow-up was 9 months (range, 0.2-32). Treatment-related adverse events (AEs) of any grade and grade 3/4 occurred in 123 (64%) and 24 (13%) patients, respectively. No deaths were attributed to treatment-related AEs. ORR was 18% (34/192; 95% CI, 13-24%). Median response duration was not reached (range, 2+ to 30+ months); 85% of responses lasted ≥6 months. Overall survival at 12 months was 38%. Conclusions: Some patients received 2 years of treatment and the responses were ongoing for more than 30 months; the durable anti-tumour activity and tolerable safety profile, observed with long-term follow-up, support the use of pembrolizumab as a treatment for recurrent/metastatic HNSCC.

Original languageEnglish (US)
Pages (from-to)153-159
Number of pages7
JournalBritish journal of cancer
Volume119
Issue number2
DOIs
StatePublished - Jul 17 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012'. Together they form a unique fingerprint.

  • Cite this

    Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B., Tahara, M., Keam, B., Kang, H., Muro, K., Geva, R., Chung, H. C., Lin, C. C., Aurora-Garg, D., Ray, A., Pathiraja, K., Cheng, J., Chow, L. Q. M., & Haddad, R. (2018). Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012. British journal of cancer, 119(2), 153-159. https://doi.org/10.1038/s41416-018-0131-9